Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure

Azzouzi, Abdel-Rahmène; Lebdai, Souhil; Benzaghou, Fawzi; Stief, Christian G.

doi:10.1007/s00345-015-1535-2

Cited by 82 publications

(45 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the dose escalation phase, 3 patients received single fiber, 2 mg/kg WST11, 200 J/cm light and 6 patients received 2 mg/kg WST11, 300 J/cm light (single or multifiber). Based upon cumulative data from PCM202 and concurrent ongoing European trials 20 , dose escalation was discontinued following the multifiber - 2mg/kg WST11 - 300 J/cm dose group by the DSMB and the trial sponsor, as it was felt that reproducible, confluent necrosis could be achieved at an optimal dosing of multiple laser fibers, 4 mg/kg WST11, and 200 J/cm energy, and that further escalation would risk toxicity without perceived benefit in efficacy. A total of 21 patients were thus treated at the optimal dose.…”

Section: Resultsmentioning

confidence: 99%

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States

et al. 2016

Self Cite

View full text Add to dashboard Cite

Introduction Vascular targeted photodynamic therapy (VTP) with WST11 (TOOKAD® Soluble; STEBA Biotech, Luxembourg) is a form of tissue ablation that may be used therapeutically for localized prostate cancer (PCa). To study dosing parameters and associated treatment effects we undertook a prospective multicenter phase I/II trial of WST11 VTP for treatment of PCa Methods 30 men with unilateral, low volume, Gleason 3+3 PCa were enrolled at 5 centers following local IRB approval. Light energy, fiber number, and WST11 dose were escalated to identify optimal dosing parameters for VTP hemiablation. Men were treated by VTP and evaluated by post-treatment MRI and biopsy. PSA, light dose index (LDI-defined as sum of fiber length/ desired treatment volume), toxicity, and quality of life parameters were recorded. Results Following dose escalation, 21 men received optimized dosing of 4 mg/kg WST11 200 J energy. On post-treatment biopsy, residual PCa was found in the treated lobe in 10 men, untreated lobe in 4, and both lobes in 1. When LDI ≥ 1, at optimal dosing, (n=15), 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment, with optimal dose and LDI ≥ 1, had negative post-treatment biopsy. Minimal effects on urinary, sexual function, and overall quality of life, were observed. Conclusions Hemiablation of the prostate with WST11 VTP was well-tolerated and resulted in negative biopsy in the treated lobe for the majority of men. Dosing parameters and LDI appear related to tissue response as determined by MRI and biopsy. These parameters may serve as the basis for further prospective studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The lead-containing bacteriophaeophorbide derivative known as TOOKAD [25] and its newer water-soluble derivative known as TOOKAD Soluble have been tested in clinical trials for prostate cancer [26]. The new bacteriochlorin derivative known as LUZ11 [27] recently entered clinical trials for head and neck cancer in Portugal (Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer, Clinical Trials.Gov NCT02070432).…”

Section: Tetrapyrrole Structuresmentioning

confidence: 99%

New photosensitizers for photodynamic therapy

Abrahamse

Hamblin

2016

Biochemical Journal

1,665

1,172

View full text Add to dashboard Cite

Photodynamic therapy (PDT) was discovered more than 100 years ago, and has since become a well-studied therapy for cancer and various non-malignant diseases including infections. PDT uses photosensitizers (PSs, non-toxic dyes) that are activated by absorption of visible light to initially form the excited singlet state, followed by transition to the long-lived excited triplet state. This triplet state can undergo photochemical reactions in the presence of oxygen to form reactive oxygen species (including singlet oxygen) that can destroy cancer cells, pathogenic microbes and unwanted tissue. The dual-specificity of PDT relies on accumulation of the PS in diseased tissue and also on localized light delivery. Tetrapyrrole structures such as porphyrins, chlorins, bacteriochlorins and phthalocyanines with appropriate functionalization have been widely investigated in PDT, and several compounds have received clinical approval. Other molecular structures including the synthetic dyes classes as phenothiazinium, squaraine and BODIPY (boron-dipyrromethene), transition metal complexes, and natural products such as hypericin, riboflavin and curcumin have been investigated. Targeted PDT uses PSs conjugated to antibodies, peptides, proteins and other ligands with specific cellular receptors. Nanotechnology has made a significant contribution to PDT, giving rise to approaches such as nanoparticle delivery, fullerene-based PSs, titania photocatalysis, and the use of upconverting nanoparticles to increase light penetration into tissue. Future directions include photochemical internalization, genetically encoded protein PSs, theranostics, two-photon absorption PDT, and sonodynamic therapy using ultrasound.

show abstract

“…The photosensitizer is infused intravenously while the targeted prostate zone is illuminated by trans-perineal optical fibers. 3 The photosensitizer absorbs light and transfers energy to oxygen molecules creating reactive oxygen species and inducing irreversible endothelial damage which is quickly followed by thrombosis, blood stasis, and vessel occlusion, ultimately leading to tumor necrosis. [4][5][6] Results from multiple phase II clinical trials in prostate cancer patients treated by VTP hemiablation show that a high rate of patients have no detectable tumors years after therapy compared to the untreated population.…”

Section: Introductionmentioning

confidence: 99%

Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

2019) Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer, OncoImmunology, 8:6, e1581528, ABSTRACT Vascular-targeted photodynamic therapy (VTP) induces rapid destruction of targeted tissues and is a promising therapy for prostate cancer. However, the resulting immune response, which may play an important role in either potentiating or blunting the effects of VTP, is still incompletely understood. Myeloid cells such as myeloid-derived suppressor cells (MDSCs) and macrophages are often found in tumors and are widely reported to be associated with cancer angiogenesis, tissue remodeling, and immunosuppression. These cells are also known to play a critical role in wound-healing, which is induced by rapid tissue destruction. In this study, we investigated the effects of VTP on the recruitment of tumorinfiltrating myeloid cells, specifically MDSCs and tumor-associated macrophages (TAMs), in the Myc-Cap and TRAMP C2 murine prostate cancer models. We report that VTP increased the infiltration of myeloid cells into the tumors, as well as their expression of CSF1R, a receptor required for myeloid differentiation, proliferation, and tumor migration. As anti-CSF1R treatment has previously been used to deplete these cells types in other murine models of prostate cancer, we hypothesized that combining anti-CSF1R with VTP therapy would lead to decreased tumor regrowth and improved survival. Importantly, we found that targeting myeloid cells using anti-CSF1R in combination with VTP therapy decreased the number of tumor MDSCs and TAMs, especially M2 macrophages, as well as increased CD8 + T cell infiltration, decreased tumor growth and improved overall survival. These results suggest that targeting myeloid cells via CSF1R targeting is a promising strategy to potentiate the anti-tumor effects of VTP. ARTICLE HISTORY

show abstract

Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure

Cited by 82 publications

References 11 publications

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States

New photosensitizers for photodynamic therapy

Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer

Contact Info

Product

Resources

About